Participants with diabetic macular edema treated with a senolytic Bcl-xL inhibitor in the phase 2 BEHOLD study experienced visual acuity improvement after 18 weeks, according to a press release from Unity Biotechnology.
The study enrolled 65 participants who were actively treated with anti-VEGF therapy and had a visual acuity deficit and residual retinal fluid.
After a single injection of UBX1325, participants experienced a mean improvement in best corrected visual acuity of 6.1 letters from baseline at 18 weeks compared with 1.1 letters in participants treated with sham (P = .0368). In